CADPS Antikörper (AA 151-250)

Produktnummer ABIN1385753

Produktdetails anti-CADPS Antikörper

Target: CADPS (Ca++-Dependent Secretion Activator (CADPS))

Bindungsspezifität: AA 151-250

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CADPS Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Frozen Sections) (IHC (fro))

Homologie: Human,Mouse,Rat,Dog,Cow,Sheep,Pig,Horse,Chicken

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human CAPS1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IHC-F 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Haltbarkeit: 12 months

Details zu CADPS

Target: CADPS (Ca++-Dependent Secretion Activator (CADPS))

Andere Bezeichnung: CAPS1 (CADPS Produkte)

Hintergrund:

Synonyms: Cadps, CADPS1, Calcium dependent secretion activator 1, Calcium-dependent activator protein for secretion 1, Calcium-dependent secretion activator 1, Caps, CAPS-1, rCAPS, CAPS1_HUMAN.

Background: Calcium-dependent secretion activators (CAPS-1 and CAPS-2) are calcium-binding proteins that direct neurotransmitter and neuropeptide-filled vesicles to the cell membrane for secretory granule exocytosis. Both CAPS-1 and CAPS-2 are expressed primarily in the brain where they regulate the secretion of various substances. The CAPS proteins contain a PH domain that is essential for regulation of exocytosis, as well as regulation of phospholipid binding. Through their regulation of neurotrophin release from granule cells, CAPS proteins help to regulate cell fate during neuronal development. CAPS-1 is thought to regulate catecholamine release from neuronal cells, while CAPS-2 is thought to regulate release of both brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) from granule cells. Defects in the genes encoding CAPS-1 and CAPS-2 are implicated in impaired cerebral development and autism.

Pathways: Synaptic Vesicle Exocytosis